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EatA, an Immunogenic Protective Antigen of Enterotoxigenic
Escherichia coli, Degrades Intestinal Mucin
Pardeep Kumar,a Qingwei Luo,a Tim J. Vickers,a Alaullah Sheikh,b Warren G. Lewis,a James M. Fleckensteina,b,c
Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USAa; Microbial Pathogenesis Program, Division of
Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, Missouri, USAb; Medicine Service, Veterans Affairs Medical Center, St. Louis,
Missouri, USAc
Enterotoxigenic Escherichia coli (ETEC) is a major cause of morbidity and mortality due to infectious diarrhea in developing
countries for which there is presently no effective vaccine. A central challenge in ETEC vaccinology has been the identification of
conserved surface antigens to formulate a broadly protective vaccine. Here, we demonstrate that EatA, an immunogenic secreted
serine protease of ETEC, contributes to virulence by degradingMUC2, the major protein present in the small intestinal mucous
layer, and that removal of this barrier in vitro accelerates toxin access to the enterocyte surface. In addition, we demonstrate that
vaccination with the recombinant secreted passenger domain of EatA (rEatAp) elicits high titers of antibody and is protective
against intestinal infection with ETEC. These findings may have significant implications for development of both subunit and
live-attenuated vaccines against ETEC and other enteric pathogens, including Shigella flexneri, that express similar proteins.
Infectious diarrhea continues to cause substantial morbidity andremains a leading cause of death among children in areas where
clean water and sanitation are limited (1, 2). EnterotoxigenicEsch-
erichia coli (ETEC) infections range in severity from asymptom-
atic colonization to severe, cholera-like diarrhea (3, 4) and death
that ensues from rapid dehydration. Currently, it is estimated that
these infections are responsible for millions of infections and hun-
dreds of thousands of deaths, particularly among children under
the age of 2 years (5–7). While in general the death rate from
diarrheal illness has declined (1, 8), these infections are still com-
monly associated with severe dehydrating forms of illness similar
to Vibrio cholerae (9, 10). Recent data from the large Global En-
teric Multicenter Study reaffirm the important role that these
infections play particularly in young children (12). ETEC in-
fections have also been shown to play a significant part in the
complex association between malnutrition and repeated bouts
of diarrheal illness among young children in developing coun-
tries (13, 14).
ETEC bacteria are defined by the production heat-stable toxin
(ST) and/or heat-labile toxin (LT) enterotoxins that elicit in-
creases in cyclic nucleotides cyclic GMP (cGMP) and cyclic AMP
(cAMP), respectively, in target intestinal epithelial cells. Activa-
tion of cyclic-nucleotide-dependent cellular kinases results in ac-
tivation of the cystic fibrosis transmembrane regulatory (CFTR)
channel leading to chloride efflux into the intestinal lumen with
commensurate decreased absorption of sodium and water, ulti-
mately resulting in profuse watery diarrhea (15).
Currently, there are no vaccines to protect against these impor-
tant pathogens (16, 17). Most vaccines thus far have specifically
targeted a relatively small group of antigens, namely, plasmid-
encoded surface antigens known as colonization factors (CFs), or
the heat-labile toxin. While prior infections with ETEC do appear
to offer protection against subsequent infection (6, 18, 19), recent
vaccine studies would suggest that the precise nature of this pro-
tection and the protective antigens involved are still being defined
(20). Moreover, recent immunoproteomic studies (21) suggest
that the immune response to ETEC infections is complex and
involves recognition of multiple antigens, including both classical
antigens, such as LT and the CF, and a number of novel patho-
type-specific antigens.
One of the antigens identified in these studies, EatA, appears to
be relatively conserved in the ETEC pathovar (22) and is repre-
sented by a geographically diverse collection of ETEC strains (23).
Earlier studies demonstrated that EatA is a member of a family of
molecules referred to as serine protease autotransporters of the
Enterobacteriaceae (SPATE) (24). These molecules serve a variety
of virulence functions in different enteric pathogens. EatA appears
to modulate both adherence to epithelial cells and intestinal col-
onization in part by digesting EtpA, a novel exoprotein adhesin
molecule that is secreted by ETEC (25).
However, a number of factors would suggest that this picture is
incomplete and that EatA could have additional functions. First,
while many strains that possess the eatA gene also encode the
etpBAC two-partner secretion locus (26) responsible for produc-
tion and secretion of EtpA, some do not. Furthermore, EatA ho-
mologues are present in other bacteria which do not make EtpA
including Shigella (SepA) (27), strains of enteroaggregative E. coli
(EAEC) associated with more severe diarrheal illness (28), and
Shiga toxin-producing E. coli serotype O104:H4 strains that re-
cently emerged in outbreaks of hemolytic-uremic syndrome
(HUS) (29). Collectively, these data would suggest that EatA and
similar molecules play an important common role in the patho-
genesis of these enteric pathogens.
Here we demonstrate that EatA degrades MUC2, the major
mucin secreted by intestinal epithelium. These data potentially
provide an explanation for the widespread distribution of EatA
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and its homologues in a variety of mucosal pathogens and suggest
that targeting of intestinal mucins may be critical to their viru-
lence.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Bacterial strains used in these
studies are outlined in Table 1. ETEC strain H10407, originally isolated
from a patient with severe cholera-like diarrheal illness in Bangladesh
(30), was kindly supplied from stocks of this strain maintained at the
Walter Reed Army Institute of Research according to good manufacturing
practices by Stephen Savarino.
Maintenance andpropagation of human cell lines.LS174T intestinal
epithelial cells (31) were propagated in Eagle’s minimum essential me-
dium (E-MEM) supplemented with 10% (final concentration) fetal bo-
vine serum (FBS). Jurkat cells were propagated in RPMI 1640 medium
supplemented with 10% FBS. All cells were cultivated at 37°C in a 5% CO2
atmosphere.
Purification of recombinant EatA passenger domain. Recombi-
nant EatA passenger domain (rEatAp) was purified from E. coli
LMG194fliC(pSP014) (25) culture supernatants by ultrafiltration, fol-
lowed by the addition of ammonium sulfate to 80% saturation and cen-
trifugation. Pellets containing rEatAp were redissolved in 50 mM sodium
phosphate and 200 mM NaCl and further purified by gel filtration chro-
matography (HiLoad 16/60 Superdex 200 prep grade; GE Life Sciences) in
the same buffer. The passenger domain of the rEatApH134R mutant
(rEatAp with a passenger domain mutation within the known catalytic site
at histidine residue 134 [H134R]) was purified in an identical manner
from E. coli LMG194fliC(pSP019). When required, additional purifica-
tion was performed by anion exchange. rEatAp in 25 mM imidazole (pH
7.0) was applied to a 5-ml column (HiTrap Q HP), and bound protein was
then eluted over a linear 0 to 1 M gradient of NaCl in the same buffer.
Protein purity was assessed by SDS-PAGE, and purified protein was buffer
exchanged against phosphate-buffered saline (PBS) (pH 7.4) containing
10% glycerol before storage at80°C.
Antibody purification. Polyclonal rabbit antisera raised against a
fragment of the EatA passenger domain (24) was cross absorbed against
an immobilizedE. coli lysate column (Thermo Scientific) and then affinity
purified using the passenger protein immobilized on nitrocellulose as
previously described (25, 32).
Isolation of mucin. To isolate intestinal gel-forming mucin MUC2,
medium supernatants from tissue culture of LS174T cells (ATCC CL-188)
that produce abundant MUC2 (33, 34), were first concentrated by ultra-
filtration using a 100-kDa-molecular-weight cutoff (MWCO) filter. Fol-
lowing buffer exchange with 10 mM Tris-HCl and 250 mM NaCl (pH
7.4), size exclusion chromatography was performed using Sepharose CL-2B
(35). Fractions containing intact MUC2 as confirmed by immunoblotting
TABLE 1 Bacterial strains and plasmids used in these studies




H10407 Wild-type ETEC strain O78:H11; CFA/I; LT/ST; EtpA; EatA 30, 52
TOP10 FmcrA (mrr-hsdRMS-mcrBC) 80lacZM15 lacX74 recA1 araD139 (ara leu)7697 galU galK rpsL (Strr) Invitrogen
jf904 H10407 eatA::Cmr mutant 24
jf876 H10407 lacZYA::Kmr 39
Plasmids
pBAD/Myc-HisA Arabinose-inducible expression plasmid Invitrogen
pSB001 7,064-bp BamHIlac subclone from pBAD-TOPO/lacZ/V5-His 25
pSP014 4,185-bp eatA amplicon cloned into pBAD-TOPO 24
pSP019 pSP014 altered by SDM for His-134¡Arg-134 substitution of EatA 24
a Strr, streptomycin resistance; Cmr, chloramphenicol resistance; Kmr, kanamycin resistance; SDM, site-directed mutagenesis.
FIG 1 EatA degrades the major intestinal mucin MUC2. (a) EatA is a serine protease autotransporter protein with an N-terminal signal peptide (SP) passenger
domain containing the predicted HDS catalytic triad and C-terminal -domain required for extracellular secretion of passenger domain. (b) Immunoblot
showing the degradation of MUC2 (black arrow) in lysates of LS174T cell monolayers treated with recombinant EatA passenger domain (rEatAp) compared to
mock (ø) treatment. The positions of molecular mass markers (in kilodaltons) are indicated to the left of the blot. (c and d) Abundant cell-associated MUC2
(green) on the surfaces of mock-treated LS174T cells (c) is depleted following the addition of recombinant rEatAp passenger domain (d). Shown at the left of each
panel are individual z-stack images, while composite yz and xz reconstructions are shown to the right and at the bottom of each panel, respectively. Nuclei are
stained blue, and cell membranes are shown in red.
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using anti-MUC2 antibody (described below) were pooled and saved at
80°C.
Mucin degradation. Degradation of purified MUC2 was examined by
adding various amounts of rEatAp to 0.2 g of purified MUC2 in 20-l
final reaction mixture volume in PBS (pH 7.4) and incubating at 37°C for
the indicated time. The reaction digest was resolved on 3 to 8% Tris-
acetate gradient gel (NuPAGE; Invitrogen) and transferred to nitrocellu-
lose, and MUC2 degradation products were visualized by immunoblot-
ting using anti-MUC2 rabbit polyclonal (IgG) antibody (H-300 [catalog
no. sc-15334; Santa Cruz]) (1:2,000) that recognizes an epitope corre-
sponding to amino acids 4880 to 5179 mapping at the C terminus of
mucin 2 of human origin (gene identification [ID] 4583). To inhibit ser-
ine protease activity of rEatAp, 4-amidino-phenylmethanesulfonyl fluo-
ride hydrochloride (APMSF) was used at a final concentration of 100M.
A previously constructed active site mutant rEatApH134R (24) was also
tested for its protease activity as described above. Degradation of cell-
associated MUC2 was carried out by treating confluent monolayers of
LS174T cells grown in 96-well plates with rEatAp (50 g/ml final concen-
tration in MEM without FBS) for 3 h or overnight at 37°C. Cells were lysed
by boiling in SDS-PAGE sample buffer, and immunoblotting was per-
formed as described above.
Substrate specificity of EatA. In order to study substrate specificity of
rEatAp, we used fluorescein isothiocyanate (FITC)-labeled substrates, in-
cluding casein, IgG, gelatin, and bovine submaxillary mucin (BSM) in a
kinetic assay based on the release of fluorescence from quenched sub-
strates due to proteolysis as previously described (36).
We also tested other glycoproteins as potential substrates for rEatAp,
including IgA, lactoferrin, and heavily glycosylated mucin-like protein
CD43 expressed at the surfaces of human T lymphocytes (37). Briefly,
bovine lactoferrin (Sigma) or human IgA (Sigma) was dissolved at 0.5
mg/ml in 100 l of 100 mM morpholinepropanesulfonic acid (MOPS)
and 200 mM NaCl (pH 7.3). Digests were initiated by the addition of
either 5 g rEatAp or 1 g proteinase K and then incubated at 37°C.
Samples were removed at intervals, the reaction was stopped by boiling in
SDS-PAGE buffer, and the products were separated by SDS-PAGE and
visualized by Coomassie blue staining.
To test CD43 degradation, 1 106 Jurkat cells were incubated for 3 h
at 37°C and 5% CO2 with 5 g of rEatAp diluted in a total volume of 100
l of RPMI 1640 medium without FBS, a protocol similar to that outlined
by Szabady et al. (38). The cells were pelleted at 400 g for 5 min, washed
with PBS, and blocked with 1% BSA in PBS, and cell surface CD43 was
then labeled with phycoerythrin-conjugated anti-CD43 (mouse anti-hu-
man CD43 monoclonal clone L10; Invitrogen) and analyzed by flow cy-
tometry.
In vitroMUC2 degradation. LS174T cells were treated with rEatAp or
rEatApH134R (at a final concentration of 50 g/ml) or vehicle control
(PBS) for 3 h and examined by immunofluorescence confocal microscopy
with anti-MUC2 rabbit polyclonal antibody (IgG) (H-300 [catalog no.
sc-15334; Santa Cruz]). Images were saved as z-stacks, and image data
were then analyzed using Volocity three-dimensional (3D) image analysis
software (version 6.2; PerkinElmer, Inc.).
Binding of labeled cholera toxin binding to epithelial cells. LS174T
cells were treated with rEatAp (at a final concentration of 5 g/ml) or
vehicle control (PBS) for 3 h as described above and examined by immu-
nofluorescence confocal microscopy using cholera toxin B subunit con-
jugated with Alexa Fluor 488 (Life Technologies). Images were saved as
z-stacks, and image data were then analyzed using Volocity 3D image
analysis software (version 6.2; PerkinElmer, Inc.).
Cellular cytotoxicity assay. To examine rEatAp-treated cells for po-
tential cytotoxicity, LS174T cells were grown to confluent monolayers in
96-well plates. After the tissue culture medium was removed, the cells
were treated with prewarmed MEM alone or supplemented with rEatAp
(25 or 50 g/ml) for 3 h at 37°C and 5% CO2. Triton X-100 (at final
concentration of 0.1%) was used as a positive control. After the cells were
treated, the medium was aspirated, and the cells were treated with 0.5
mg/ml MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bro-
mide) in MEM with 10% FBS at 37°C and 5% CO2 for 30 min. The
medium was aspirated immediately, and the cells were washed with 200l
of PBS. Cells were lysed by adding 200 l dimethyl sulfoxide (DMSO),
and optical density at 630 nm (OD630) was recorded with DMSO alone as
a blank. Data represent percentage of the mock-treated cells from tripli-
cate experiments.
EatA induction studies. In order to test whether intestinal mucins can
induce secretion of EatA by ETEC, we grew overnight cultures of ETEC
H10407 in M9 medium containing 0.2% glucose for 3 h, and then the
medium was supplemented with purified MUC2 (final concentration of 2
g/ml). Samples of culture supernatant were collected at indicated time
points, precipitated with trichloroacetic acid (TCA), and used to detect
secreted EatA by immunoblotting using affinity-purified EatA antibody.
FIG 2 Mucin degradation by EatA requires serine protease activity. Using
concentrated culture supernatant from the eatA mutant, we observed no
MUC2 degradation compared to that from WT ETEC H10407. (a) Comple-
mentation of the eatAmutant with WT EatA (pSP014), but not H134R mutant
EatA (pSP019) or vector control (pSB001), restored activity. (b) H134R mu-
tant EatA (pSP019) purified from E. coli LMG194fliC was unable to degrade
MUC2 compared to WT EatA (pSP014). (c) rEatAp degrades purified MUC2
in a dose-dependent fashion. Untreated MUC2 is shown in the leftmost lane
(lane 0) followed by serial dilutions of rEatAp passenger domain starting at 4.5
nmol/ml of protein. (d) Protease activity of rEatAp was inhibited by APMSF.
(e) MUC2 is degraded in a time-dependent manner (samples obtained at 0, 5,
10, and 20 minutes) by the purified passenger domain of recombinant wild-
type EatA (rEatAp) but not by the purified active-site mutant protein
(rEatApH134R). (f) EatA degrades cell-associated MUC2. Abundant MUC2
(green) on the surfaces of untreated LS174T cells and monolayers treated with
recombinant H134R mutant EatA passenger protein (rEatApH134R) compared
to cells treated with recombinant wild-type EatA passenger domain (rEatAp).
The images shown in panel f are Volocity-generated 3D projections from
z-stacks.
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Immunization and intestinal colonization of mice. Groups of 10
CD-1 mice were immunized intranasally with either PBS, 1 g of heat-
labile toxin (LT), or 1g of LT plus 30g of rEatAp on days 0, 14, and 28.
On day 42, mice were pretreated with streptomycin; the mice were given
streptomycin (5 g per liter) in drinking water for 24 h, followed by drink-
ing water alone for 12 h. Fecal samples (6 pellets/mouse) were collected on
day 42, resuspended in buffer (10 mM Tris, 100 mM NaCl, 0.05% Tween
20, 5 mM sodium azide [pH 7.4]) overnight at 4°C, and then centrifuged
the next day to pellet insoluble material and recover supernatant to test
fecal antibody response (see below). After administration of famotidine to
reduce gastric acidity, mice were challenged with 	105 CFU of the lac-
ZYA::Kmr jf876 (39) strain by oral gavage. Twenty-four hours after infec-
tion, the mice were sacrificed, their sera were collected, and dilutions of
saponin intestinal lysates (40) were plated onto Luria agar plates contain-
ing kanamycin (25 g/ml).
Immune responses to EatA and LT were determined using previously
described kinetic enzyme-linked immunosorbent assay (ELISA) (41, 42).
Briefly, ELISA wells were coated with 1 g/ml of rEatAp or LT in 0.1 M
NaHCO3 buffer (pH 8.6) overnight at 4°C. The next day, the wells were
washed three times with Tris-buffered saline containing 0.005% Tween 20
(TBS-T), blocked with 1% bovine serum albumin (BSA) in TBS-T for 1 h
at 37°C, and 100l of fecal suspensions (undiluted) or sera (diluted 1:100
in TBS-T with 1% BSA) was added per ELISA well and incubated at 37°C
for 1 h. Horseradish peroxidase-conjugated secondary antibodies were
used, and signal was detected with TMB (3,3=,5,5=-tetramethylbenzi-
dine)-peroxidase substrate (KPL) substrate.
To examine any differences in clearance of wild-type (WT) and eatA
mutant strains, we monitored fecal shedding of bacteria by infected mice.
Briefly, mice were challenged with either the lacZYA::Kmr strain or eatA::
Cmr mutant bacteria at 105 CFU/dose, and stools (6 fecal pellets/mouse)
were collected at days 1, 2, 3, 4, and 5 postinfection, resuspended in phos-
phate-buffered saline, and plated onto agar containing kanamycin (25
g/ml) or chloramphenicol (15 g/ml).
RESULTS
EatA preferentially degrades MUC2 intestinal mucin. Previous
studies of EatA demonstrated that this protease was associated
with enhanced intestinal fluid accumulation and epithelial cell
FIG 3 Mucin-degrading activity of EatA is pH dependent. Anti-MUC2 im-
munoblot demonstrates cleavage of MUC2 (top band) in the presence of re-
combinant EatA (rEatAp). Control lanes at each pH are shown (no rEatAp
added [ lanes]).
FIG 4 Specificity of rEatAp activity. (a and b) EatA lacks the ability to degrade lactoferrin (a) or IgG (b). Proteinase K (pr.K) activity is shown as a positive control
for each of these substrates in Coomassie blue-stained gel images. Small black arrows to the right of the gels indicate the respective substrate bands, while small
white arrows in the leftmost lane show the migration of the rEatAp passenger domain. (c) Degradation of FITC-labeled substrates casein, BSM, gelatin, and IgA
by the bacterial protease subtilisin (as evident by an increase in fluorescence) but not rEatAp. PMSF, phenylmethylsulfonyl fluoride. (d) Fluorescence-activated
cell sorting (FACS) data demonstrating loss of mucin-like glycoprotein CD43 from the surfaces of Jurkat cells following proteinase K treatment but not rEatAp.
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destruction in the rabbit ileal loop model (24). One possible ex-
planation for these findings is that EatA could enhance access to
enterocytes by degradation of the mucin barrier in the small in-
testine. To test this hypothesis, we first examined the ability of
purified rEatAp (Fig. 1a) to degrade the major mucin present in
the small intestinal lumen, MUC2. Treatment of LS174T cell
monolayers with rEatAp significantly reduced the amount of
MUC2 associated with these cells (Fig. 1b to d) as detected by
immunoblotting of cellular lysates (Fig. 1b) and by confocal mi-
croscopy (Fig. 1c and d).
Deletion of eatA in ETEC H10407 resulted in significant loss of
its MUC2-degrading activity. Concentrated culture supernatants
from the H10407 strain degraded MUC2, while those obtained
from the eatA mutant grown under identical conditions had no
appreciable activity (Fig. 2a). Likewise, eatA mutant complemen-
tation with pSP014 expressing rEatAp regained the ability to de-
grade MUC2, while complementation with the plasmid (pSP019)
expressing mutant rEatApH134R with a passenger domain muta-
tion within the known catalytic site at histidine residue 134
(H134R) or the vector alone (pSB001) failed to rescue this pheno-
type. Similarly, purified rEatAp from a recombinant E. coli
LMG194fliC strain expressing pSP014 showed activity against
mucin, while rEatApH134R purified from LMG194fliC(pSP019)
displayed no activity (Fig. 2b).
Purified rEatAp degraded MUC2 in a dose-dependent fashion
(Fig. 2c). Mucin degradation by rEatAp was inhibited by the ad-
dition of the serine protease inhibitor APMSF (Fig. 2d). Consis-
tent with the previously described proteolytic activity of EatA,
rEatApH134R was completely deficient in the ability to degrade
MUC2 over time (Fig. 2e and f).
Recombinant rEatAp passenger domain exhibited its greatest
proteolytic activity against MUC2 at neutral to slightly acidic pH
(Fig. 3), consistent with the environment of the small intestine
(43). However, with this pH range, we were not able to demon-
strate activity against other substrates, including IgA, IgG, casein,
gelatin, lactoferrin, mucin-like glycoprotein CD43, or commer-
cially available bovine submaxillary mucin (Fig. 4), indicating a
high specificity of rEatAp for human intestinal mucin MUC2.
We also examined the effect of mucin on growth of wild-type
and eatA mutant strains of ETEC. We saw no evidence that sup-
plementation of media with purified MUC2 enhanced growth of
either strain (data not shown). Likewise, the addition of MUC2 to
growth media failed to stimulate the secretion or production of
EatA by ETEC (data not shown).
FIG 5 rEatA treatment enhances cholera toxin binding to epithelial cells. (a) rEatAp treatment enhanced cholera toxin subunit B-Alexa Fluor 488 (AF488)
conjugate (green) binding to LS174T cells (bottom row) compared to untreated cells (top row). (b) Quantification of signal intensity by Volocity software shows
a significant increase in cholera toxin subunit B (CTB) binding to rEatAp-treated LS174T cells compared to untreated cells (P less than 0.0001). The dotted
horizontal line shows the mean value for the group of mice. Each symbol represents the value for an individual mouse. (c) MTT cytotoxicity assay. rEatAp
treatment of LS174T cells does not cause cellular toxicity (Triton X-100 [TX100] is shown as a positive control).
Kumar et al.
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EatAenhances toxin access to epithelial cells.Both heat-labile
toxin (LT) and the closely related cholera toxin (CT) must engage
GM1 ganglioside receptors on the surfaces of intestinal epithelial
cells for their cellular activity. We reasoned that degradation of
MUC2 on the surfaces of epithelial cells would unmask these re-
ceptors and promote enterotoxin binding. Indeed, treatment of
epithelial cells with rEatAp significantly enhanced access of labeled
cholera toxin B subunit to cognate receptors on the cell surface
(Fig. 5a and b). In contrast, as might be predicted from its lack of
homology to known cytotoxins in this class of proteins (44),
rEatAp had no effect on the integrity of target epithelial cells, sug-
gesting that it lacks any direct cytopathic effect (Fig. 5c).
EatA is highly immunogenic and a protective antigen. ETEC
virulence is thought to require bacterial transit to the mucosal
surface where these organisms directly engage enterocytes to ef-
fectively deliver LT and ST to receptors on the surfaces of these
cells. In theory, the ability to degrade mucin would accelerate this
process by promoting direct access of the bacteria to the entero-
cyte surface. Theoretically, bacteria that are incapable of degrad-
ing mucin would be quickly eliminated from the intestine as they
are propelled along the intestinal lumen by peristaltic flow (45).
However, we found that in a murine ETEC infection model, the
eatA mutant appeared in only slightly greater numbers in stool
(Fig. 6a) and while the mutant was eliminated somewhat faster
than the wild-type ETEC parent (Fig. 6b), these differences in fecal
shedding were not statistically different.
Nevertheless, we also questioned whether neutralization of
EatA activity could serve as an effective complement to existing
vaccine strategies, which so far have primarily targeted either the
toxins themselves or fimbrial adhesin molecules (16, 17). Because
we have recently shown that EatA is recognized by antibody pres-
ent in convalescent-phase sera from patients following ETEC in-
fection (21), we examined whether vaccination with rEatAp would
offer protection against ETEC infection of the small intestinal mu-
cosa in the murine model.
As predicted by earlier studies, immunization with rEatAp gen-
erated robust serum and mucosal antibody responses (Fig. 7a to
d). More importantly, we found that mice vaccinated with rEatAp
demonstrated significantly reduced small intestinal colonization
following challenge with ETEC (Fig. 7e). Collectively, these data
provide additional evidence suggesting that EatA plays a signifi-
cant role in the pathogenesis of ETEC and potentially other im-
portant enteric pathogens that make very similar molecules.
DISCUSSION
Intestinal mucin represents a major host defense mechanism that
significantly limits interaction of both commensal and pathogenic
organisms with enterocytes to maintain mucosal integrity (46,
47). MUC2, the predominant gel-forming mucin present in the
lumen of the small intestine (46, 48, 49) forms a complex multi-
meric glycoprotein network that bacterial pathogens must navi-
gate if they are to effectively engage epithelial cells. Enteric patho-
gens have evolved a number of mechanisms to counter this barrier
(46). These mechanisms include glycosidases to degrade oligosac-
charide residues and peptidases that degrade the peptide back-
bone of these complex glycoproteins.
MUC2 is the major gel-forming mucin in both the small and
large intestine. The core region of this molecule is heavily glyco-
sylated and very resistant to the action of proteases, while interac-
tions of the C-terminal and N-terminal ends contribute to the
FIG 6 Impact of eatA on fecal shedding and clearance. (a) CFU/ml of fecal suspensions from 10 mice following oral (gavage) challenge with equal numbers of
either wild-type (wt) ETEC H10407 strain or eatA mutant strain. The dotted horizontal lines represent the mean values (CFU/ml) for the groups of mice. Each
symbol represents the value for an individual mouse. Mice with no organisms detected are shown at the theoretical lower limit of detection (1 or 100 CFU/ml).
There was no statistically significant difference (ns) between the values for the groups by Mann-Whitney two-tailed testing. (b) Percentage of mice shedding
measurable amount of ETEC in stool over 5 days after challenge.
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formation of dimers and polymers of MUC2, respectively (49).
Additional study will be needed to determine whether EatA
cleaves MUC2 at either the unprotected amino or carboxy ter-
mini, similar to a cysteine protease of Entamoeba histolytica (49).
Our studies demonstrate that vaccination with the passenger
domain of EatA, which possesses MUC2-degrading activity, af-
forded significant protection against infection of the small intes-
tinal mucosa in the murine model. However, we should point out
that it is not clear from these studies that this relates directly to
neutralization of EatA enzymatic activity. Earlier studies of the
ability of EatA to modulate adhesion, toxin delivery, and intestinal
colonization by degrading the EtpA adhesin (25) would suggest
that this enzyme potentially plays a complex role in the pathogen-
esis of ETEC. Moreover, despite the robust activity of EatA in
degradation of human MUC2 in vitro, the anticipated impact on
fecal shedding in mice proved to be modest, potentially relating to
structural differences in the major gel-forming mucins of mice
and humans or differential enzymatic activity in the complex en-
vironment of the intestine. Additional effort will likely be required
to address the impact of EatA and related proteases on these very
complex phenotypes.
EatA is a member of the serine protease autotransporters of the
Enterobacteriaceae (SPATE) family of proteins. Another SPATE
protein that is shared by both enteroaggregativeE. coli and Shigella
flexneri, Pic, has been shown to degrade a number of substrates,
including mucins (50). However, unlike Pic, we were unable to
demonstrate that EatA had any activity against bovine submaxil-
lary mucin. These results are consistent with earlier studies of the
EatA homologue SepA (44). Although several SPATE molecules,
including Pic, have been shown to target a number of glycopro-
teins rich in O-linked glycans involved in the leukocyte trafficking
and inflammation (37), this property is not shared by SepA, sug-
gesting that these proteins may target a different class of mole-
cules. Indeed, EatA was incapable of degrading the mucin-like
CD43 molecule in our studies. Collectively, these findings suggest
that enteric pathogens have evolved divergent mechanisms to ad-
dress the barrier imposed by intestinal mucins.
EatA shares approximately 80% homology to SepA, a serine
protease of Shigella flexneri. Similar to EatA of ETEC, the SepA
Shigella homologue appeared to accelerate fluid accumulation in
the ileal loop model of infection (24, 27). Although the exact func-
tion of SepA in Shigella pathogenesis is still unknown, our studies
could suggest that SepA may be involved in degradation of MUC2
covering the colonic mucosa, the preferential site for Shigella col-
onization.
Additional molecular epidemiology studies may attest to the
importance of EatA as a virulence determinant in ETEC and other
enteric pathogens. In otherwise heterogeneous collections of
ETEC from Chile (23) and Guinea Bissau (22), eatA genes were
present in more than 70% of ETEC strains. Recently, EatA homo-
logues have been identified in enteroaggregative E. coli associated
with more-severe infections (28) and in serotype O104 Shiga tox-
in-producing E. coli that emerged suddenly in food-borne out-
breaks in Europe (29). These organisms likely share in their need
to penetrate mucin to cause severe infections. While ETEC infec-
tions may range from mild clinical illness to severe cholera-like
diarrhea (3) associated with rapid dehydration, the contribution
of eatA to the more severe manifestations is not clear at present.
Nevertheless, the clear association of these organisms with death
due to severe diarrheal illnesses in young children (12) provides a
strong impetus to understand which virulence factors might con-
tribute to these more life-threatening phenotypes.
As noted in our accompanying paper (53), ETEC strains also
encode the type II secretion system effector protein YghJ, a met-
alloprotease which also degrades intestinal mucins. Collectively,
these studies provide further corroborative evidence that the abil-
ity to breach the physical barrier imposed by mucins is an impor-
tant virulence attribute for enteric pathogens, including entero-
toxigenic E. coli.
Four decades after the discovery of ETEC (51), a broadly pro-
tective vaccine for ETEC has yet to be developed (16). The identi-
fication of novel immunogens and elucidation of the contribution
FIG 7 Immunogenicity and protective efficacy of recombinant EatA passen-
ger (rEatAp) domain. (a to d) Kinetic ELISA data (expressed as Vmax in milli-
units/min) demonstrate antibody in samples from mice vaccinated with either
LT alone (1 g/dose), LT plus rEatAp (1 g LT plus 30 g rEatAp/dose), or
PBS. The immunogen used is shown on the x axis of each graph. Serum (IgG,
IgM, and IgA) responses (at 1:100 dilution of sera) to LT (a) and rEatAp (b)
and fecal (IgA) responses (undiluted samples) to rEatAp (c) and LT (d) are
shown. 
LT, anti-LT antibody. (e) LT/rEatAp-immunized mice were pro-
tected against colonization by ETEC following intestinal challenge with jf876
(data obtained 24 h after challenge; P 0.0063 by Mann-Whitney two-tailed
nonparametric analysis).
Kumar et al.
506 iai.asm.org Infection and Immunity
 o
n
 April 20, 2014 by W







of EatA and other antigens to virulence and protective immunity
should inform rational approaches to ETEC vaccinology.
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